CP-001 Impact of a pharmaceutical care programme focused on solid organ transplant patients
| Autor: | I. Font-Noguera, P García-Gómez, M Montero-Hernández, José Luis Poveda-Andrés, C Planells-Herrero, M.J. Fernández-Megía, C Sáez-Pons, M.J. Cuéllar-Monreal |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
medicine.medical_specialty Interventional cardiology business.industry media_common.quotation_subject Retrospective cohort study Transplantation Pharmaceutical care Cardiothoracic surgery Organ Survival Emergency medicine medicine General Pharmacology Toxicology and Pharmaceutics Intensive care medicine business Solid organ transplantation media_common |
| Zdroj: | European Journal of Hospital Pharmacy. 22:A1.1-A1 |
| ISSN: | 2047-9964 2047-9956 |
| DOI: | 10.1136/ejhpharm-2015-000639.1 |
| Popis: | Background Patient and organ survival is dependent on the use of immunosuppressant drugs. The doses are reduced several months after the surgery to low maintenance phase levels. Treatments are complex and require drug treatment monitoring. Purpose To analyse the impact of a Pharmaceutical Care Programme focused on solid organ transplant patients for the prevention and correction of drug-related problems (DRPs). DRPs include medication errors in the process of prescribing, dispensing or administering a drug. Material and methods Study design: retrospective observational study. Sample: 222 solid organ transplant patients: 94 kidney (9 with pancreas), 31 lung, 86 liver and 19 heart. The IASER method (identify, act, monitor, evaluate and results) was used as a tool to analyse and categorise the DRPs. Variables: number and type of DRP, drugs, recommended actions, acceptance and cost savings (acquisition drug cost, preparation and administration time cost, GRD cost, etc. Results 125 DRPs were detected in 88 patients (0.5 problem/solid organ transplant patient). 60.8% of the patients were males and the average of age was 53 years (7–86). Identified by validation (71.2%) and analytical parameters (24.0%). 41.6% of DRPs reached the patient. The main problems were over dosage (24%) in kidney transplant and (8%) in liver transplant patients, the need for additional treatment (12%) in lung transplant and (1.6%) in heart transplant patients. The DRPs were categorised into safety (45.6%), indication (33.6%), effectiveness (18.4%) and adherence (2.4%). The therapeutic groups involved were mainly antibiotics (50%) and immunosuppressants (26%). 81.6% of the actions were accepted by physicians. 72% were relevant to improving patient care. The financial impact was €69,826/year saved (€38,123/year in kidney transplant, €19,106/year in lung transplant, €9,658/year in liver transplant and €2,939/year in heart transplant patients). Conclusion Management of complex treatments requires the involvement of all health professionals. A pharmaceutical care programme based on pharmacotherapeutic monitoring resolved DRPs in solid organ transplant patients. It improved the quality of treatment and saved money. References and/or acknowledgements No conflict of interest. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|